Overview

• The observational cohort comprised 452,777 overweight and obese adults followed over 10 years, with 35,784 dementia cases and 76,048 deaths recorded.
• Metformin use was linked to an 8–12% lower risk of dementia across all BMI categories from 25 to 40 and above.
• Users of metformin experienced 26–28% lower all-cause mortality compared with matched nonusers.
• Age-stratified analyses indicated that adults under 65 with BMIs of 30–39.9 saw significant reductions in dementia risk when using metformin.
• Researchers propose that metformin’s anti-inflammatory and antioxidative properties underlie its neuroprotective effects and highlight its low cost of $2–$20 per month for broad accessibility.